Apollomics company info

What does Apollomics do?
Apollomics (NASDAQ:APLM) focuses on the discovery, development, and commercialization of oncology treatments and therapies, aiming to reshape the landscape of cancer care. The company is devoted to advancing a robust pipeline of novel therapeutic compounds, including targeted approaches for various cancers, leveraging cutting-edge research and technology. With projects ranging from early-stage discovery to clinical development, Apollomics seeks to improve outcomes for patients battling this challenging disease. The objective is to deliver innovative solutions that address unmet medical needs, transforming how cancer is treated and offering hope to patients and their families.
Apollomics  company media
Company Snapshot

Is Apollomics a public or private company?

key
Ownership
Public

How many people does Apollomics employ?

people
Employees
45

What sector is Apollomics in?

pie chart
Sector
Health Care

Where is the head office for Apollomics ?

location pin
Head Office
Foster City, United States

What year was Apollomics founded?

founded flag
Year Founded
2015
What does Apollomics specialise in?
/Cancer Therapeutics /Drug Discovery /Medical Research /Clinical Development /Oncology Drugs /Collaborative Projects

What are the products and/or services of Apollomics ?

Overview of Apollomics offerings
Cancer Drug Discovery & Development: Apollomics focuses on creating new drugs for cancer treatment. They identify potential targets and develop drug candidates through preclinical and clinical trials.
Immuno-oncology Focus: Their research leans towards leveraging the body's immune system to fight cancer.
Clinical Trial Pipeline Management: They manage a pipeline of drug candidates undergoing clinical trials to assess safety and effectiveness.
Collaboration Potential: Apollomics may collaborate with other pharmaceutical companies for further development or licensing of their drugs.
Partnerships for Development: They might partner with other organizations to expedite research or clinical trials.
Intellectual Property Portfolio Building: As they develop drugs, Apollomics builds a portfolio of intellectual property to protect their innovations.

Who is in the executive team of Apollomics ?

Apollomics leadership team
  • Dr. Guo-Liang  Yu Ph.D.
    Dr. Guo-Liang Yu Ph.D.
    Co-Founder, CEO & Executive Chairman
  • Dr. Sanjeev  Redkar MBA, Ph.D.
    Dr. Sanjeev Redkar MBA, Ph.D.
    Co-Founder, President & Executive Director
  • Dr. Matthew James Plunkett Ph.D.
    Dr. Matthew James Plunkett Ph.D.
    Chief Financial Officer
  • Dr. Kin-Hung  Yu M.D.
    Dr. Kin-Hung Yu M.D.
    Chief Medical Officer
  • Dr. Chinglin  Lai Ph.D.
    Dr. Chinglin Lai Ph.D.
    Senior Vice President of Biostatistics & Data Management